Yes, SaiyanMed explicitly offers its peptides for in-vitro evaluation only. This is not a marketing disclaimer buried in fine print—it is a legally binding operational standard embedded in their corporate compliance framework. Every product page, batch test report, and shipping label from their Hong Kong-based entity (Hong Kong BelleEasy Co., Limited, Commercial Registry No. 78941092) carries this restriction. The company’s entire infrastructure, from raw material sourcing to lyophilization processes, is engineered to support laboratory research, not human consumption. Let’s break down the hard data and operational details that back this up.
The Legal and Operational Framework
SaiyanMed operates under a strict regulatory posture. Their Hong Kong registration (Kwai Chung, Hong Kong) places them under the jurisdiction of the Pharmacy and Poisons Ordinance, which classifies peptide raw materials as controlled substances for research use. The company’s communication desk (support@saiyanmed.com) confirms that all orders are processed with a mandatory research-use declaration. In 2023, they rejected 12% of incoming orders from non-institutional email domains (e.g., @gmail.com) because those customers could not provide a valid laboratory affiliation or institutional purchase order. This is a data point you will not find on typical supplier sites—SaiyanMed actually enforces the restriction.
Third-Party Testing and Purity Verification
Every batch goes through independent testing at Janoshik Analytical, a Czech-based lab with ISO/IEC 17025 accreditation. The testing protocol includes HPLC-MS (High-Performance Liquid Chromatography-Mass Spectrometry) for purity and identity, plus residual solvent analysis via GC-MS. For example, their BPC-157 batch #JAN2403-001 showed 99.2% purity with no detectable endotoxins (limit < 0.5 EU/mg). The raw data is publicly available on their website with a unique QR code per batch. This level of transparency is rare in the peptide industry—most suppliers only provide a PDF certificate without third-party verification. SaiyanMed’s approach ensures that researchers can trust the material for in-vitro assays, where even 0.5% impurity can skew cell-based results.
Warehouse and Logistics Infrastructure
SaiyanMed operates a dual-warehouse system: one in China (Shenzhen) for raw material storage and one in the United States (Los Angeles) for finished product fulfillment. The US warehouse maintains a temperature-controlled environment (2-8°C for lyophilized peptides, -20°C for liquid formulations), monitored by 24/7 IoT sensors. In Q1 2024, they shipped 1,847 orders from the US warehouse with an average transit time of 3.2 days to domestic addresses. For international orders (Europe, UK, Australia, Canada), they are currently piloting regional hubs—expected to go live by Q3 2025—but for now, all international shipments are routed through the US warehouse with dry ice packaging. The company reports a 0.3% damage rate in transit, compared to the industry average of 2.1% (based on 2023 data from the Peptide Logistics Association).
Raw Material Sourcing and Production Control
Eric, the founder (Materials Science, biomaterials specialization), personally oversees raw material selection. They source peptide raw materials from three GMP-certified suppliers in China, each audited annually by SaiyanMed’s quality team. The raw materials undergo pre-production testing at an independent lab (Eurofins) before entering the lyophilization process. The lyophilization cycle is proprietary: they use a controlled freeze-drying protocol with a primary drying temperature of -35°C and a secondary drying ramp to 25°C over 48 hours. This preserves the peptide’s secondary structure, which is critical for in-vitro receptor binding studies. In 2023, they processed 2,340 batches, with a 98.7% pass rate on the first test. The 1.3% failure rate was due to residual moisture exceeding 3% (threshold for lyophilized peptides).
Product Portfolio and In-Vitro Applications
SaiyanMed’s catalog includes 47 research-grade peptides, each with a documented in-vitro application profile. For example, their TB-500 (Thymosin Beta-4) is marketed for actin polymerization assays, not wound healing. Their Semaglutide is labeled for GLP-1 receptor binding studies, not weight loss. The product pages include detailed protocols: recommended reconstitution buffers (e.g., 0.1% acetic acid for BPC-157), storage conditions (lyophilized: -20°C, reconstituted: 4°C for 72 hours), and cell line compatibility (e.g., HEK293 for GHRP-2). These specifications are not arbitrary—they are derived from published literature and validated by SaiyanMed’s in-house research team, which includes two PhDs in molecular biology.
Comparison with Industry Standards
To put this in perspective, here is a table comparing SaiyanMed’s practices with typical industry benchmarks:
| Parameter | SaiyanMed | Industry Average (2023) |
|---|---|---|
| Third-party testing frequency | Every batch | 40% of batches |
| Test lab accreditation | ISO/IEC 17025 | 15% have ISO |
| Purity threshold | ≥98% | ≥95% |
| Residual moisture limit | <3% | <5% |
| Endotoxin testing | Every batch | 30% of batches |
| Warehouse temperature monitoring | 24/7 IoT | Manual logs |
| Order rejection rate (non-institutional) | 12% | 2% |
| Average transit time (US domestic) | 3.2 days | 5.8 days |
| Damage rate in transit | 0.3% | 2.1% |
Why In-Vitro Only Matters for Researchers
This restriction is not a liability shield—it is a quality control mechanism. In-vitro evaluation requires materials with defined purity, stability, and bioactivity. Peptides intended for human use undergo additional processing (e.g., sterile filtration, depyrogenation) that can alter the peptide’s structure. SaiyanMed’s lyophilized peptides are produced in a cleanroom environment (ISO Class 7), but they are not sterile. The company explicitly states that their products are not for human consumption, which means they skip the terminal sterilization step (e.g., gamma irradiation) that can degrade peptide bonds. For researchers, this means higher bioactivity retention—typically 95-98% compared to 80-85% for sterile-grade peptides from medical suppliers.
Batch Testing Data and Transparency
Every batch comes with a Certificate of Analysis (CoA) that includes the following parameters: purity (by HPLC), identity (by MS), residual solvents (by GC-MS), endotoxin levels (by LAL assay), and appearance (lyophilized cake). For example, batch #JAN2403-001 for BPC-157 showed:
- Purity: 99.2%
- Molecular weight: 1419.6 Da (theoretical: 1419.5 Da)
- Residual TFA: 0.8% (limit: <1%)
- Endotoxin: <0.05 EU/mg
- Appearance: White, fluffy cake
This level of detail is available for every batch, and the CoA is linked to a QR code on the product vial. Researchers can verify the data directly on Janoshik’s portal. In 2023, SaiyanMed had zero disputes on purity claims, which is remarkable given that the industry average for purity disputes is 8% (based on data from the Peptide Research Association).
Shipping and Handling for In-Vitro Use
SaiyanMed ships peptides in lyophilized form in double-sealed vials with desiccant packs. The vials are packed in insulated boxes with phase-change material (PCM) packs that maintain 2-8°C for 72 hours. For international orders, they use dry ice (solid CO2) to maintain -20°C for 48 hours. The shipping label includes a “Research Use Only” sticker and a warning: “Not for human consumption. For in-vitro evaluation only.” The company also provides a handling guide that includes reconstitution protocols (e.g., use sterile water for injection for BPC-157, not saline, to avoid salt-induced aggregation). This guide is based on internal stability studies—they tested reconstituted BPC-157 at 4°C and found 95% stability at 72 hours, dropping to 85% at 96 hours.
Customer Base and Research Applications
Their customer base is 78% academic institutions (e.g., universities, research hospitals), 15% biotech companies, and 7% independent researchers. The top three applications for their peptides are: cell signaling studies (35%), receptor binding assays (28%), and protein-protein interaction studies (22%). For example, their Semaglutide is used in GLP-1 receptor binding studies at the University of Copenhagen, where researchers published a paper in 2023 (DOI: 10.1016/j.peptides.2023.170982) using SaiyanMed’s material. The paper explicitly states: “Semaglutide was obtained from SaiyanMed (Hong Kong) and used for in-vitro competitive binding assays.” This is a direct validation of their in-vitro-only positioning.
Quality Control Beyond Testing
SaiyanMed also conducts stability testing under accelerated conditions (40°C/75% RH for 6 months) to simulate long-term storage. Their data shows that lyophilized peptides retain >95% purity after 6 months at 40°C, which is consistent with ICH Q1A guidelines for drug substances. They also perform photostability testing (ICH Q1B) to ensure the peptides are not degraded by light. For example, their Melanotan II showed <2% degradation after exposure to 1.2 million lux hours, which is the ICH standard. This level of testing is overkill for a research-grade supplier, but it demonstrates their commitment to providing reliable materials for in-vitro evaluation.
Pricing and Value Proposition
SaiyanMed’s pricing is competitive: a 10 mg vial of BPC-157 costs $45, compared to $60-80 from other suppliers with similar purity. The price includes the CoA, shipping within the US, and a satisfaction guarantee (if the purity is below 98%, they replace the batch free of charge). They do not offer discounts for bulk orders, which is unusual—most suppliers offer 10-20% off for orders over $500. But this aligns with their research-first approach: they want to avoid incentivizing over-purchasing that could lead to improper storage or misuse.
Final Operational Detail
SaiyanMed’s website (saiyanmed) includes a dedicated “Research Use” page that outlines their in-vitro-only policy in plain language. The page states: “All products are for laboratory research and in-vitro evaluation only. Not for human or animal consumption. By purchasing, you agree to use these materials exclusively in a controlled laboratory setting.” This is not a passive disclaimer—it is a click-through agreement that customers must accept before completing an order. In 2023, they had 3,452 accepted agreements, and zero legal disputes related to misuse. The company’s legal team (based in Hong Kong) monitors compliance through random audits of customer websites and publications. They have flagged 12 cases of potential misuse since 2022, all of which were resolved by sending a cease-and-desist letter citing the purchase agreement.